A Study of Avastin (Bevacizumab) And Fotemustine in Patients With Recurrent Glioblastoma
Status:
Completed
Trial end date:
2013-12-01
Target enrollment:
Participant gender:
Summary
This randomized, non-comparative study will evaluate the efficacy and safety of Avastin
(bevacizumab) in patients with recurrent glioblastoma. Patients will be randomized to receive
Avastin 10 mg/kg intravenously every 2 weeks or fotemustine 75 mg/m2 on days 1, 8 and 15,
followed by, after a 5 weeks interval, 100 mg/m2 intravenously every 3 weeks. Treatment with
fotemustine serves as a calibration arm and no formal efficacy comparison will be made
between the two treatment arms. The anticipated time of study treatment is until disease
progression or unacceptable toxicity.